Literature DB >> 33712900

Association between adropin and coronary artery lesions in children with Kawasaki disease.

Maoling Yang1,2, Qiongfei Pei1,2, Jing Zhang1,2, Haobo Weng1,2, Fengchuan Jing1,2, Qijian Yi3,4.   

Abstract

Kawasaki disease (KD) is an acute systemic vasculitis in children. Coronary artery lesions (CALs) are the most serious complications in KD, but the pathogenesis is still unclear so far. Adropin, a new biopeptide, plays an important role in metabolism and cardiovascular function. The aim of this study was to explore the relationship between adropin and KD. 66 KD patients and 22 healthy controls (HCs) were included in the study. KD patients were divided into KD with coronary artery lesions (KD-CALs) group and KD without CALs (KD-NCALs) group. The levels of serum adropin were determined by enzyme-linked immunosorbent assay (ELISA). Compared with the HC group, adropin concentrations were significantly increased in the KD group (p < 0.05), and the KD-CAL group had higher levels of adropin than those in the KD-NCAL group (p < 0.05). Pct (Procalcitonin) and DD (D-dimer) were positively correlated with adropin in the KD group (p < 0.05). Moreover, adropin had positive correlations with CRP (C-reactive protein) and DD in the KD-NCAL group and positive correlations with Pct, PLR (platelet-to-lymphocyte ratio), and DD in the KD-CAL group (p < 0.05). The receiver operating characteristic (ROC) curve showed that the best threshold value of serum adropin level was more than 2.8 ng/mL, with 72.2% sensitivity and 71.4% specificity for predicting CALs in children with KD.
Conclusion: Adropin might be involved in the pathogenesis of KD and CALs and can be used as an auxiliary diagnostic biomarker of KD. What is Known: • CALs in KD were mainly caused by inflammation, immune imbalance, and vascular endothelial dysfunction, and adropin is involved in metabolic diseases and cardiovascular diseases. What is New: • In this study, we have found the relationship between adropin and KD, and serum adropin level can be used as an auxiliary diagnostic biomarker to predict CALs in KD.

Entities:  

Keywords:  Adropin; Children; Coronary artery lesions; Kawasaki disease

Mesh:

Substances:

Year:  2021        PMID: 33712900     DOI: 10.1007/s00431-021-03977-5

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  29 in total

1.  Relationship between mean platelet volume-to-lymphocyte ratio and coronary artery abnormalities in Kawasaki disease.

Authors:  Gulcin Bozlu; Derya Karpuz; Olgu Hallioglu; Selma Unal; Necdet Kuyucu
Journal:  Cardiol Young       Date:  2018-04-16       Impact factor: 1.093

2.  Endothelial and platelet function in children with previous Kawasaki disease.

Authors:  Marianna Laurito; Alessandra Stazi; Angelica B Delogu; Maria Milo; Irma Battipaglia; Giancarla Scalone; Fabio Infusino; Angelo Villano; Giulio Russo; Rossella Iannotta; Annalisa Saracino; Rossella Parrinello; Stefano Figliozzi; Alfonso Sestito; Costantino Romagnoli; Gaetano A Lanza; Filippo Crea
Journal:  Angiology       Date:  2013-09-09       Impact factor: 3.619

3.  Expression of adropin in rat brain, cerebellum, kidneys, heart, liver, and pancreas in streptozotocin-induced diabetes.

Authors:  Suleyman Aydin; Tuncay Kuloglu; Suna Aydin; Mehmet Nesimi Eren; Musa Yilmaz; Mehmet Kalayci; Ibrahim Sahin; Nevin Kocaman; Cihan Citil; Yalcin Kendir
Journal:  Mol Cell Biochem       Date:  2013-04-26       Impact factor: 3.396

4.  Coagulopathy and platelet activation in Kawasaki syndrome: identification of patients at high risk for development of coronary artery aneurysms.

Authors:  J C Burns; M P Glode; S H Clarke; J Wiggins; W E Hathaway
Journal:  J Pediatr       Date:  1984-08       Impact factor: 4.406

Review 5.  Salusins and adropin: New peptides potentially involved in lipid metabolism and atherosclerosis.

Authors:  Leszek Niepolski; Alicja E Grzegorzewska
Journal:  Adv Med Sci       Date:  2016-04-03       Impact factor: 3.287

6.  Antidiabetic and hypolipidemic effects of adropinin streoptozotocin-induced type 2 diabetic rats.

Authors:  R Akcilar; F E Kocak; H Simsek; A Akcilar; Z Bayat; E Ece; H Kokdasgil
Journal:  Bratisl Lek Listy       Date:  2016       Impact factor: 1.278

7.  Novel bioactive substances in human colostrum: could they play a role in postnatal adaptation?

Authors:  Despina D Briana; Maria Boutsikou; Theodora Boutsikou; Antonios Marmarinos; Dimitrios Gourgiotis; Ariadne Malamitsi-Puchner
Journal:  J Matern Fetal Neonatal Med       Date:  2016-05-05

8.  A comparison of the predictive validity of the combination of the neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio and other risk scoring systems for intravenous immunoglobulin (ivig)-resistance in Kawasaki disease.

Authors:  Seiichiro Takeshita; Takashi Kanai; Yoichi Kawamura; Yusuke Yoshida; Shigeaki Nonoyama
Journal:  PLoS One       Date:  2017-05-23       Impact factor: 3.240

Review 9.  Pathogenetic determinants in Kawasaki disease: the haematological point of view.

Authors:  Domenico Del Principe; Donatella Pietraforte; Lucrezia Gambardella; Alessandra Marchesi; Isabella Tarissi de Jacobis; Alberto Villani; Walter Malorni; Elisabetta Straface
Journal:  J Cell Mol Med       Date:  2017-01-07       Impact factor: 5.310

Review 10.  Adropin- A Novel Biomarker of Heart Disease: A Systematic Review Article.

Authors:  Somaye Yosaee; Sepideh Soltani; Eghbal Sekhavati; Shima Jazayeri
Journal:  Iran J Public Health       Date:  2016-12       Impact factor: 1.429

View more
  4 in total

1.  The association between serum adropin and carotid atherosclerosis in patients with type 2 diabetes mellitus: a cross‑sectional study.

Authors:  Wen Wei; Hui Liu; Xiuping Qiu; Jushun Zhang; Jianqing Huang; Hangju Chen; Shuilin Qiu; Ruiyu Lin; Shihai Li; Mei Tu
Journal:  Diabetol Metab Syndr       Date:  2022-02-08       Impact factor: 3.320

Review 2.  Adropin's Role in Energy Homeostasis and Metabolic Disorders.

Authors:  Ifrah Ismail Ali; Crystal D'Souza; Jaipaul Singh; Ernest Adeghate
Journal:  Int J Mol Sci       Date:  2022-07-28       Impact factor: 6.208

3.  Diagnostic accuracy of adropin as a preliminary test to exclude acute pulmonary embolism: a prospective study.

Authors:  Serhat Orun; Aliye Celikkol; Batuhan Ilbey Basol; Elif Yeniay
Journal:  BMC Pulm Med       Date:  2022-09-18       Impact factor: 3.320

Review 4.  Current Knowledge of Selected Cardiovascular Biomarkers in Pediatrics: Kidney Injury Molecule-1, Salusin-α and -β, Uromodulin, and Adropin.

Authors:  Mirjam Močnik; Nataša Marčun Varda
Journal:  Children (Basel)       Date:  2022-01-13
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.